Chronic obstructive pulmonary disease (COPD) is a chronic lung condition characterized by loss of lung elasticity, which leads to dysfunctional gaseous exchange. COPD is the third leading cause of ...

There was a notable gap in effectiveness between metered-dose and dry-powder formulations of single-inhaler triple therapy for chronic obstructive pulmonary disease (COPD), according to real-world ...

Leah J. Witt, MD: Hello. I'm Dr Leah Witt. Welcome to season one of Medscape InDiscussion, chronic obstructive pulmonary disease (COPD) podcast series. Today we're talking medications, especially ...

Please provide your email address to receive an email when new articles are posted on . Invited patients had 32% of days covered for maintenance inhalers, whereas control patients had a smaller ...

Researchers explained that educational level, duration of disease, and inhaler type may affect adherence in patients with chronic obstructive pulmonary disease (COPD). Most patients with chronic ...

Please provide your email address to receive an email when new articles are posted on . Less than 40% of the studied veteran cohort were adherent to their inhaled COPD medications. Adherence was found ...

Medicare Part D and Medicare Advantage (Part C) plans with drug coverage typically cover inhalers for COPD. But you may still be responsible for a portion of the cost. If you have chronic obstructive ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved the world’s first low-carbon version of a triple-combination inhaler for chronic obstructive pulmonary disease (COPD). The ...

Various types of inhalers, including short- and long-lasting options, are available for managing chronic obstructive pulmonary disease (COPD). A person can get a COPD inhaler through Medicare Part D ...

Chronic obstructive pulmonary disease (COPD) treatments involving inhaled corticosteroids (ICSs) were associated with a greater risk for fractures, a meta-analysis of several dozen randomized trials ...

Asthma and COPD Drugs Market is expected to reach US$ 82.2 Billion by 2036, driven by Advancements in Drug Discovery and ...